Your browser doesn't support javascript.
loading
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma, Hayley S; Poudel, Bibhav; Torres, Evanthia Roussos; Sidhom, John-William; Robinson, Tara M; Christmas, Brian; Scott, Blake; Cruz, Kayla; Woolman, Skylar; Wall, Valerie Z; Armstrong, Todd; Jaffee, Elizabeth M.
Afiliación
  • Ma HS; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Poudel B; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Torres ER; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Sidhom JW; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Robinson TM; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Christmas B; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Scott B; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Cruz K; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Woolman S; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Wall VZ; Benaroya Research Institute at Virginia Mason, Seattle, Washington.
  • Armstrong T; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Jaffee EM; Department of Oncology, Viragh Center for Pancreatic Clinical Research and Care, Bloomberg Kimmel Institute for Immunotherapy, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland. ejaffee@jhmi.edu.
Cancer Immunol Res ; 7(3): 428-442, 2019 03.
Article en En | MEDLINE | ID: mdl-30642833

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos Infiltrantes de Tumor / Antígenos CD40 / Microambiente Tumoral / Receptor de Muerte Celular Programada 1 / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cancer Immunol Res Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos Infiltrantes de Tumor / Antígenos CD40 / Microambiente Tumoral / Receptor de Muerte Celular Programada 1 / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cancer Immunol Res Año: 2019 Tipo del documento: Article